Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 5/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786459 | 0.94 | KMO (0.39) | HDAC2HDAC3HDAC1ESR2HDAC4 | |
| SCHEMBL3791039 | 0.86 | QDPR (0.33) | QDPRHDAC2HDAC3HDAC1ESR2 | |
| SCHEMBL3788813 | 0.82 | QDPR (0.41) | QDPRHDAC2HDAC3HDAC1ESR2 | |
| SCHEMBL3785466 | 0.81 | ACMSD (0.38) | HDAC2HDAC3HDAC1ESR2HDAC4 | |
| SCHEMBL3788494 | 0.75 | HDAC8 (0.42) | QDPRHDAC2HDAC1HDAC4HDAC8 | |
| SCHEMBL3791565 | 0.75 | QDPR (0.39) | QDPRHDAC2ESR2HDAC4HDAC8 | |
| SCHEMBL3790400 | 0.74 | KMO (0.44) | QDPRHDAC2HDAC1HDAC4HDAC8 | |
| SCHEMBL3787278 | 0.72 | ABCB1 (0.32) | — | |
| SCHEMBL3787947 | 0.71 | CHRNB2 (0.30) | — | |
| SCHEMBL3793166 | 0.71 | QDPR (0.41) | QDPRHDAC2HDAC3HDAC1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | QDPR 339/4885HDAC2 549/4885HDAC3 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.